Cost regulators for NHS treatments in England and Wales are standing by their position that Orexigen’s weight loss pill Mysimba can not be recommended as a cost-effective treatment option.
The National Institute for Health and Care Excellence has published draft guidelines turning down Orexigen’s weight loss pill Mysimba for routine NHS use.